Myriad Genetics, Inc. Overview
Company Headquarters: Utah, US
Founded: 1991
Workforce: 2,400+
Company Working: Myriad Genetics, Inc. (Myriad) is one of the first few genomics companies pioneering in molecular diagnostics. Myriad is one of the leaders in molecular diagnostics with product offerings in the therapeutic areas such as hereditary cancer, urological cancer, lung cancer, autoimmune disorders, and other diseases. In 1996, Myriad introduced the first molecular diagnostic test for hereditary breast and ovarian cancer. The test, BRACAnalysis was widely accepted and later approved by FDA for the companion diagnostics for breast cancer. The company has international headquarters located in Switzerland. Additionally, the Company has laboratories in Austin (Texas), Munich (Germany), Salt Lake City (UT), South San Francisco (CA). Myriad is present in 128 countries and serves its customers through its subsidiaries and distributors.
Strategy
Myriad’s strategy is focused on five critical success factors-building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit sales internationally, and improving profitability. The company is also focused on becoming a trusted advisor for transforming the lives of the patients worldwide with its pioneering diagnostic products.
